newsfilter
← Latest News
Business Wire·

Axcella Reports First Quarter Financial Results and Provides Business Update

Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarte